

Sex disparities in cardiovascular risk factor assessment and screening for diabetes-related complications in individuals with diabetes: a systematic review

Jong, M. de; Peters, S.A.E.; Ritter, R. de; Kallen, C.J.H. van der; Sep, S.J.S.; Woodward, M.; ...; Vos, R.C.

Citation

Jong, M. de, Peters, S. A. E., Ritter, R. de, Kallen, C. J. H. van der, Sep, S. J. S., Woodward, M., ... Vos, R. C. (2021). Sex disparities in cardiovascular risk factor assessment and screening for diabetes-related complications in individuals with diabetes: a systematic review. *Frontiers In Endocrinology*, *12*. doi:10.3389/fendo.2021.617902

Version:Publisher's VersionLicense:Creative Commons CC BY 4.0 licenseDownloaded from:https://hdl.handle.net/1887/3250620

Note: To cite this publication please use the final published version (if applicable).





Sex Disparities in Cardiovascular Risk Factor Assessment and Screening for Diabetes-Related Complications in Individuals With Diabetes: A Systematic Review

Marit de Jong¹, Sanne A. E. Peters^{1,2,3}, Rianneke de Ritter^{4,5}, Carla J. H. van der Kallen^{4,5}, Simone J. S. Sep^{4,5,6}, Mark Woodward^{2,3,7}, Coen D. A. Stehouwer^{4,5}, Michiel L. Bots¹ and Rimke C. Vos^{1,8*}

OPEN ACCESS

Edited by:

Tine Willlum Hansen, Steno Diabetes Center Copenhagen (SDCC), Denmark

Reviewed by:

Hidetaka Hamasaki, Hamasaki Clinic, Japan Jan Brož, Charles University, Czechia

> *Correspondence: Rimke C. Vos R.C.Vos@lumc.nl

Specialty section:

This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology

Received: 15 October 2020 Accepted: 11 February 2021 Published: 30 March 2021

Citation:

de Jong M, Peters SAE, de Ritter R, van der Kallen CJH, Sep SJS, Woodward M, Stehouwer CDA, Bots ML and Vos RC (2021) Sex Disparities in Cardiovascular Risk Factor Assessment and Screening for Diabetes-Related Complications in Individuals With Diabetes: A Systematic Review. Front. Endocrinol. 12:617902. doi: 10.3389/fendo.2021.617902 ¹ Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands, ² The George Institute for Global Health, Imperial College London, London, United Kingdom, ³ The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia, ⁴ Department of Internal Medicine, Maastricht University Medical Center, Maastricht, Netherlands, ⁵ CARIM Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands, ⁶ Centre of Expertise in Rehabilitation and Audiology, Adelante, Hoensbroek, Netherlands, ⁷ Department of Epidemiology, Johns Hopkins University, Baltimore, MD, United States, ⁸ Department Public Health and Primary Care / LUMC-Campus The Hagua, Leiden University Medical Center, Hague, Netherlands

Background: Insight in sex disparities in the detection of cardiovascular risk factors and diabetes-related complications may improve diabetes care. The aim of this systematic review is to study whether sex disparities exist in the assessment of cardiovascular risk factors and screening for diabetes-related complications.

Methods: PubMed was systematically searched up to April 2020, followed by manual reference screening and citations checks (snowballing) using Google Scholar. Observational studies were included if they reported on the assessment of cardiovascular risk factors (HbA1c, lipids, blood pressure, smoking status, or BMI) and/ or screening for nephropathy, retinopathy, or performance of feet examinations, in men and women with diabetes separately. Studies adjusting their analyses for at least age, or when age was considered as a covariable but left out from the final analyses for various reasons (i.e. backward selection), were included for qualitative analyses. No meta-analyses were planned because substantial heterogeneity between studies was expected. A modified Newcastle-Ottawa Quality Assessment Scale for cohort studies was used to assess risk of bias.

Results: Overall, 81 studies were included. The majority of the included studies were from Europe or North America (84%). The number of individuals per study ranged from 200 to 3,135,019 and data were extracted from various data sources in a variety of settings. Screening rates varied considerably across studies. For example, screening rates for retinopathy ranged from 13% to 90%, with half the studies reporting screening rates less

1

than 50%. Mixed findings were found regarding the presence, magnitude, and direction of sex disparities with regard to the assessment of cardiovascular risk factors and screening for diabetes-related complications, with some evidence suggesting that women, compared with men, may be more likely to receive retinopathy screening and less likely to receive foot exams.

Conclusion: Overall, no consistent pattern favoring men or women was found with regard to the assessment of cardiovascular risk factors and screening for diabetes-related complications, and screening rates can be improved for both sexes.

Keywords: diabetes, sex disparities, risk factors, diabetes-related complications, healthcare provision, screening, systematic review

INTRODUCTION

In 2019, an estimated 463 million adults aged between 20 and 79 years had diabetes, affecting 9.0% of women and 9.6% of men globally. Cardiovascular diseases (CVD) are one of the most common complications of diabetes, with individuals with diabetes being two to three times more likely to develop CVD compared to those without diabetes (1). Other common diabetes-related complications include diabetic nephropathy, retinopathy, neuropathy, certain cancers, physical and cognitive impairment, depression and several types of infectious diseases (1, 2).

Although incidence rates of major CVD have been reported to be higher in men than women with and without diabetes (3, 4), there is a growing body of evidence showing that the relative risk of major cardiovascular complications conferred by diabetes is larger in women than men (2–8). Several large studies have shown that the relative risk of ischemic heart disease conferred by diabetes can be up to 50% higher in women than men (3, 5, 8). A sex differential in the consequence of diabetes has also been reported for stroke, where the relative risk of stroke was 27% higher among women than men (6). Less is known about sex differences in the effects of diabetes on microvascular complications. A meta-analysis has demonstrated that diabetes confers a 19% higher relative risk of vascular dementia in women than men (9). Sex differences have also been shown for end-stage renal disease, but not for chronic kidney disease (10).

Underlying mechanisms that explain the higher excess risk of (vascular) complications, conferred by diabetes, in women remain uncertain but may include sex disparities in the uptake and provision of healthcare (2). Currently, many guidelines on diabetes management exist. These evidence-based guidelines provide similar recommendations for both sexes on the assessment of risk factors and screening for diabetes-related complications. Therefore, throughout this systematic review, the term "disparity" will be explicitly used to refer to differences in risk factors between men and women.

More insight in sex disparities concerning the uptake and provision of diabetes management may eventually result in more personalized diabetes care, thereby helping to further diminish the burden in both sexes. We conducted a systematic review to study whether sex disparities exist in the assessment of cardiovascular risk factors and screening for diabetes-related complications among people with diabetes.

METHODS

The protocol of this study was registered at the international prospective register of systematic reviews (PROSPERO) registry (registration number: CRD42018104414). We performed this review according to the guidelines of the preferred reporting items for systematic reviews and meta-analyses (PRISMA) (11).

Search Strategy and Study Selection

Observational studies (including before-after studies) on the assessment of cardiovascular risk factors (HbA1c, lipids, blood pressure, BMI, and smoking status), and screening for complications (retinopathy, nephropathy, and foot ulcerations/ deformities/sensory decline), in men and women with diabetes, were identified through systematically searching PubMed (1/1/ 2009 up to April 2020) (Supplemental Table I). After having identified a set of eligible studies using our search strategy, we performed manual reference and citation screening (snowballing) using Google Scholar. This method has previously been described as a good alternative to database searches once a number of eligible studies have been identified (12). Studies were included if data on the assessment of cardiovascular risk factors or screening for diabetes-related complications were provided separately for men and women. Studies presenting insufficient information about the effect size or direction of sex disparities were excluded (i.e. studies only presenting p-values). Only full-text articles written in English or Dutch were considered eligible for inclusion. Studies also including individuals without diabetes were eligible if results for individuals with diabetes were presented separately. Studies on gestational diabetes were excluded, as well as studies on which data on risk factor assessment were only adjusted for, rather than analyzed by, sex. Furthermore, studies primarily focusing on children or adolescents were excluded.

Outcomes

The outcomes of interest were; assessment of HbA1c, lipids, blood pressure, smoking status, and BMI, screening for

nephropathy, retinopathy, and performance of foot examinations, or any combination, all reported as binary variables (yes vs. no). For all outcomes of interest, we used "assessment of cardiovascular risk factors" and "screening for complications" as defined by the original article. When studies showed multiple outcome definitions, we chose the one closest to (inter)national guidelines.

Data Collection and Management

Data extraction was performed by one author (MJ) and checked by a second author (RV). Any discrepancies between the authors during data collection were discussed with a third author (SP). The extracted data comprised: authors' names and year of publication, country, study period, number of participants (% women), age, reported outcomes (including measures of association with corresponding confidence intervals (CIs)), and data source (**Supplemental Table II**).

Quality Assessment

The methodological quality of the included studies was assessed by one author (MJ) and checked by a second author (RV), using a modified Newcastle-Ottawa Quality Assessment Scale for cohort studies (13). The modified scale includes six items under three categories: selection, comparability and outcome. Any discrepancies were discussed with a third author (SP).


Data Synthesis and Analyses

It was decided beforehand not to perform any meta-analyses due to the expected heterogeneity between the included studies. Qualitative analyses were restricted to studies adjusting their analyses for age or when age was considered as an important covariable but left out from the final analyses for various reasons (i.e. backward selection). Studies only presenting crude numbers and percentages or unadjusted results are presented in **Supplemental Table III**. Where reports with overlapping study populations were found and similar outcomes of interest were studied, the study presenting data from the most recent study period or the study with most participants was included. Similarly, where studies were repeated over time, only studies with the most recent data or largest number of study participants were included. For example, the UK National Diabetes Audit is repeated every year and only data from the most recent report relevant for the outcomes of interest were extracted. Characteristics of the studies excluded from qualitative analyses are shown in **Supplemental Table IV**.

The results are presented as odds ratios (ORs) or risk ratios (RRs) with 95% CIs, with men as the reference category, unless otherwise specified. When studies only reported stratified results, e.g. by age group, ORs/RRs and the 95% CIs in each stratum were summarized using a fixed effect model. For studies that stratified the results by year, with potential overlap of included participants between strata, results from the most recent year were extracted. If studies presented multiple models, only the most extensive adjusted models were extracted. Forest plots without pooled effects were used to visualize the adjusted estimates and corresponding CIs across studies included for qualitative analysis.

RESULTS

Overall, 81 studies were included for qualitative analyses (14–92) (**Figure 1**). Characteristics of the included studies are presented in **Supplemental Table II**. The majority of studies were from Europe or Northern America (37% and 47% respectively), eight from Asia, two from Oceania, one from Africa, and one from South America. Of the 81 studies, 55 (68%) reported data on individuals with diabetes (without specifying the subtype), and 24 (30%) on individuals with type 2 diabetes. In addition, two



reports from the UK National Diabetes Audit reported data on individuals stratified by diabetes subtype. Given that no other reports presented data on individuals with type 1 diabetes, only data from individuals with type 2 diabetes were extracted from the two reports. The number of included individuals per study ranged from 200 to 3,135,019. Data were extracted from various data sources (i.e. (population-based) surveys, medical records and administrative claims data) in a variety of settings, including primary care, outpatient clinics, and hospital settings.

Risk of Bias

The risk of bias was moderate with 78% of studies showing either fair or good study quality with clearly reported information

about study design, in- and exclusion criteria, data collection, and assessment of the outcome. Although most studies included a representative sample, there was considerable heterogeneity between studies with regard to the study populations making it more challenging to score this aspect (**Supplemental Table IV**).

Assessment of HbA1c

In total, 36 studies, including 6.6 million individuals, were included with median assessment rates of 74% in women and 73% in men. Most studies showed no statistically significant sex disparities in the assessment of HbA1c (70%), while 19% showed that women were more often receiving assessment of HbA1c than men, and 11% showed that men were more often receiving assessment of HbA1c than women (**Figure 2**).

Author, year	Country	% Screened	w	м		OR/RR [95% CI]
Billimek et al., 2015	US	97	97	98	←•	0.69 [0.33, 1.45]
Bird et al., 2018a	US	86	86	86	H=1	0.84 [0.79, 0.89]
Meier et al., 2020	Switzerland	80	NR	NR	⊢ ∎–+	0.85 [0.72, 1.02]
LeBlanc et al., 2017±	Canada	61^^^	NR	NR	H	0.92 [0.89, 0.96]
Kiran et al., 2012	Canada	37	NR	NR		0.93 [0.92, 0.94]
Tanaka et al., 2016	Japan	49	NR	NR	⊢⊷⊣	0.93 [0.82, 1.04]
Whyte et al., 2019	England	69	NR	NR	=	0.94 [0.90, 0.98]
Ibáñez et al., 2018	Spain	71	72	71	 = -	0.95 [0.91, 1.00]
Wei et al., 2020	Switzerland	70	68	71	i=1	0.97 [0.93, 1.01]
Guthrie et al., 2009	Scotland	95	95	96	⊢_	0.98 [0.81, 1.19]
Van Doorn-Klomberg et al., 2015	The Netherland	s 77	NR	NR	⊢ ∎-1	0.99 [0.89, 1.09]
et al., 2015 National Diabetes Audit 2017-2018	UK	95	NR	NR		0.99 [0.98, 0.99]
Gnavi et al., 2009#	Italy	71^^	71^^	71^^	÷	1.00 [0.99, 1.01]
De Jong et al., 2019#	The Netherland	5 75	75	74	÷.	1.00 [0.98, 1.02]
Hirst et al., 2019	UK	NR	NR	NR	÷.	1.00 [0.98, 1.03]
Rossi et al., 2013	Italy	92	92	93	le-i	1.01 [0.98, 1.05]
Baviera et al., 2014	Italy	69	69	70		1.01 [0.99, 1.03]
Casanova et al., 2015	France	42	NR	NR	+	1.02 [1.01, 1.03]
Kovács et al., 2019	Hungary	78	NR	NR	H	1.02 [1.01, 1.04]
Yu et al., 2013	US	87	87	87	⊢ • • •	1.04 [0.68, 1.61]
Buja et al., 2014	Italy	61	NR	NR	=	1.05 [1.02, 1.08]
Williams et al., 2010	US	90^	NR	NR	⊢ →	1.06 [0.66, 1.72]
Bartels et al., 2012#	US	57	NR	NR	+	1.06 [1.05, 1.07]
Rossaneis et al., 2016#	Brazil	38	41	34	i⊧∎-1	1.06 [0.97, 1.16]
Tan et al., 2020	US	63	NR	NR	⊢ ∎−−1	1.06 [0.88, 1.29]
Chien et al., 2012	US	NR	NR	NR	H	1.08 [0.92, 1.24]
Naicker et al., 2014	Canada	54	53	56	⊢⊷	1.08 [0.93, 1.23]
Comer-HaGans et al., 2020	US	NR	NR	NR	⊢∔∎{	1.08 [0.87, 1.33]
Kirkbride et al., 2009	US	53	NR	NR	+	1.09 [0.96, 1.23]
Chen et al., 2014	US	70^	NR	NR	(-)	1.09 [1.05, 1.13]
Green et al., 2010	US	52	NR	NR		1.10 [1.00, 1.21]
Yoo et al., 2017	Korea	40	40	41	H=I	1.11 [1.06, 1.15]
Gold et al., 2012	US	65	NR	NR	H	1.12 [0.96, 1.30]
	US	70	NR	NR		1.17 [0.82, 1.68]

FIGURE 2 | Assessment of HbA1c, expressed as adjusted odds ratios (OR) or relative risks (RR) with corresponding 95% confidence intervals (CI). Two studies are not presented in this figure because of their measure of association: Swietek et al. (33): Average Marginal Effect, (SE; p-value): -0.00031 (-0.0044; >0.05), Du et al. (92): Prevalence difference (95% CI): 3.5 (-1.0;8.0). W = % of screened women; M = % of screened men; US, United States; UK, United Kingdom; ± = 99% CI; # = Relative risk; ^ Weighted %; ^^ = Kaplan-Meyer estimates; ^^ = Estimated %; * = statistically significant. Men = reference.

4

Assessment of Blood Pressure

The assessment of blood pressure, by sex, was reported by nine studies including 3.7 million individuals. Median assessment rate across studies was 79% (range 48% - 98%). Sex-specific percentages of blood pressure assessment were reported by three studies, ranging from 78% to 94% in women and 77% to 96% in men. Five studies showed no statistically significant disparities in the assessment of blood pressure, while three studies showed that women were more likely to receive blood pressure screening and one study reported men being more likely to receive blood pressure screening (**Figure 3**).

Assessment of Lipids

The assessment of lipids, by sex, was reported by 27 studies, including 5.4 million individuals. These studies reported on various lipid measurements, including the assessment of LDL, HDL, lipid profile, (total) cholesterol, HDL/TC-ratio, and triglycerides. Among the fifteen studies reporting the assessment of either lipids or (total) cholesterol, assessment rates ranged from 40% to 96%, with a median of 73%.

Over half the studies (8/15) reported no statistically significant or only small sex disparities, while four studies reported that, compared with men, women were less likely to receive screening, and three studies showed that women were more likely to receive screening.

Twelve studies, including data from 829,819 individuals, reported sex-specific assessment of LDL. Five studies reported that women were less likely to receive screening, four studies reported that women were more likely to receive screening than men, and the remaining three studies showed no sex disparities.

Two studies investigated sex disparities in the assessment of HDL measurements, with one reporting that women were more likely to receive screening.

One study reported on the assessment of triglycerides, showing that women were less likely to receive screening than their male counterparts (**Figure 4**).

Assessment of BMI

Two studies reported sex-specific BMI assessment; one study found that women were less likely to receive screening and the other found no sex differences (**Figure 5**).

Nephropathy Screening


Twenty studies, including 3.9 million individuals, examined sex disparities in nephropathy screening. These studies reported on various measures to assess renal function, including estimated glomerular filtration rate (eGFR), microalbuminuria, urine albumin, albumin/creatinine ration, and serum creatinine. Two-thirds of studies reported screening rates less than 70%. Overall, there was no consistent pattern in nephropathy screening favoring either women or men (**Figure 6**).

Retinopathy Screening

Fifty studies, including 3.4 million individuals, reported on retinopathy screening. Screening rates ranged from 13% to 90% across studies, with nearly half the studies reporting screening rates equal to or less than 50%. Five studies reported that women were less likely to receive retinopathy screening than men and 22 studies showed that women were more likely to receive screening (**Figure 7**).

Foot Exams


Thirteen studies, including over 3.9 million individuals, reported on the sex-specific performance of foot exams. Screening rates varied from 13% to 99% across studies, with a median screening rate of 58%. Six reported that women were less likely to receive foot exams, and one study reported women being more likely to receive foot exams. The other studies reported no sex differences (**Figure 8**).





Author, year	Country	% Screened	W	м		OR/RR [95% CI]
Lipids/(total)cholesterol						
Meier et al., 2020	Switzerland	49	NR	NR	⊢■→	0.73 [0.63, 0.85]*
Guthrie et al., 2009	Scotland	94	93	94	⊢	0.80 [0.68, 0.95] *
Bennet et al., 2017	US	NR	NR	NR	H=-1	0.87 [0.80, 0.94] *
Kiran et al., 2012	Canada	59	NR	NR	+	0.88 [0.87, 0.88] *
Chien et al., 2012	US	NR	NR	NR	⊢-∎1	0.95 [0.81, 1.09]
Rossi et al., 2013	Italy	73	72	74	H	0.97 [0.95, 0.99] *
National Diabetes Audit 2017-2018	UK	93	NR	NR	H	0.98 [0.97, 0.99] *
Baviera et al., 2014	Italy	73	72	73		0.98 [0.96, 1.00]*
De Jong et al., 2019	The Netherland	s 73	74	72	÷	1.00 [0.98, 1.02]
Gnavi et al., 2009#	Italy	65^	64^	65^	+	1.02 [1.00, 1.03]
Billimek et al., 2015	US	96	96	96	F	1.08 [0.60, 1.95]
Tanaka et al., 2016	Japan	87	NR	NR	⊢ ∎–1	1.11 [0.98, 1.25]
Rossaneis et al., 2016#	Brazil	48	52	42	⊢ ∎	1.15 [1.06, 1.27] *
Kirkbride et al., 2009	US	40	NR	NR	⊢	1.19 [1.05, 1.34] *
Reichard et al., 2012	US	52	53	48	—	1.25 [1.08, 1.44] *
LDL						
Yu et al., 2013	US	56	53	59	⊢∎⊣	0.73 [0.62, 0.85] *
Bird et al., 2018a	US	83	82	84	} ∎{	0.76 [0.71, 0.80] *
van Doorn-Klomberg et al., 2015	The Netherland	s 69	NR	NR	┝━┥	0.85 [0.78, 0.94] *
Wei et al., 2020	Switzerland	56	54	56	H=1	0.89 [0.85, 0.93] *
Casanova et al., 2015	France	78	NR	NR	#	0.93 [0.92, 0.94] *
Gold et al., 2012	US	39	NR	NR	⊢− -1	1.02 [0.88, 1.18]
Bartels et al., 2012#	US	77	NR	NR	ŧ	1.02 [1.02, 1.03] *
De Jong et al., 2019#	The Netherland	s 70	72	68	-1	1.02 [1.00, 1.05] *
Tan et al., 2020	US	31	NR	NR	⊢– ⊣	1.02 [0.86, 1.22]
Buja et al., 2014	Italy	58	NR	NR	-	1.04 [1.01, 1.07] *
Green et al., 2010	US	33	NR	NR	⊢ ∎-	1.19 [1.07, 1.31]*
HDL						
Green et al., 2010	US	36	NR	NR	┞╼╌┤	1.08 [0.98, 1.19]
De Jong et al., 2019#	The Netherland	s 63	68	57	H	1.16 [1.13, 1.19]*
Trichterider						
Triglycerides	Itoly	70	60	74		0.06 (0.04, 0.00)*
Baviera et al., 2014	Italy	70	69	71	Ħ	0.96 [0.94, 0.98] *
					r	
					0.5 1	1.5
					Men do better Wor	nen do better

FIGURE 4 | Assessment of lipids, expressed as adjusted odds ratios (OR) or relative risks (RR) with corresponding 95% confidence intervals (CI). One study is not presented in this figure because of the measure of association: Swietek et al. (33): Average Marginal Effect (LDL), (SE; p-value): 0.0045 (-0.0042; >0.05). W = % of screened women; M = % of screened men; US, United States; UK, United Kingdom; # = Relative risk; ^ = Kaplan-Meyer estimates; * = statistically significant. Men = reference.



Author, year	Country	% Screened	W	М		OR/RR [95% CI]
Nephropathy screenin	g					
Green et al., 2010	US	34	NR	NR	=	0.52 [0.47, 0.57]*
Rossi et al., 2013	Italy	41	40	42	H	0.96 [0.94, 0.97]*
Wei et al., 2020	Switzerland	44	45	44		1.07 [1.03, 1.11]*
Tomio et al., 2010	Japan	6	NR	NR		▶ 1.72 [0.82, 3.64]
(Micro)albuminuria/pro	oteinuria					
Tanaka et al., 2016	Japan	12	NR	NR	⊢=-1	0.83 [0.72, 0.94]*
National Diabetes Audit 2017-2018	UK	66	NR	NR	•	0.88 [0.88, 0.89]*
Bakke et al., 2019	Norway	32	NR	NR	⊢∎∔	0.93 [0.82, 1.05]
Baviera et al., 2014	Italy	25	24	27	н	0.95 [0.93, 0.97]*
Bilimek et al., 2015	US	77	77	78	⊢−∎┤──┤	0.95 [0.71, 1.27]
Liang et al., 2015	UK	90	90	91	H	0.96 [0.94, 0.97]*
Gnavi et al., 2009#	Italy	31^	30^	32^	H	0.96 [0.93, 0.99] *
Casanova et al., 2015	France	28	NR	NR		0.97 [0.96, 0.98]*
Rim et al.,2013	Korea	46	47	46	⊢ ∔ (1.00 [0.80, 1.40]
Yu et al., 2013	US	61	63	60	⊢ ∎	1.15 [0.99, 1.34]
Gold et al., 2012	US	16	NR	NR	⊢ ∎−-1	1.21 [0.99, 1.47]
Devkota et al., 2015	US	76	81	71	L	1.61 [0.85, 3.04]
Creatinine						
Baviera et al., 2014	Italy	69	69	69	н	0.94 [0.92, 0.96]*
Casanova et al., 2015	France	84	NR	NR	H	0.95 [0.94, 0.97]*
National Diabetes Audit 2016-2017	UK	95	NR	NR	H	1.03 [1.02, 1.05]*
Tanaka et al., 2016	Japan	84	NR	NR	⊢ ∎1	1.09 [0.97, 1.23]
Buja et al., 2014	Italy	63	NR	NR	H	1.10 [1.07, 1.14]*
Albumin/creatinine ra	tio					
Hellemons et al., 2013	The Netherla	nds 57	NR	NR	HEH	0.86 [0.79, 0.93]*
Naicker et al., 2014	Canada	57	54	59	⊦┼╼╌┤	1.08 [0.95, 1.22]
eGFR						
Whyte et al., 2019	England	66	NR	NR	H a l	0.99 [0.95, 1.03]
Naicker et al., 2014	Canada	84	83	84	⊢≢⊣	1.00 [0.89, 1.11]
					0.4 0.8 1 1.2 Men do better Women do be	1.6 etter

FIGURE 6 | Nephropathy screening, expressed as adjusted odds ratios (OR) or relative risks (RR) with corresponding 95% confidence intervals (CI). One study is not presented in this figure because of the measure of association: Swietek et al. (33): Average Marginal Effect, (SE; p-value): -0.0073 (-0.0042; <0.05 (women less likely to receive screening). W = % of screened women; M = % of screened men; US, United States; UK, United Kingdom; # = Relative risk; ^ = Kaplan-Meyer estimate. Men = reference. * = statistically significant.

Assessment of Smoking Status

Two studies reported on the assessment of smoking status. Both studies found high screening rates (95%), and women were more likely to be screened for smoking status than men (**Figure 9**).

Combination

Fifteen studies reported on the assessment of a combination of risk factors and screening activities. The presence and direction of sex disparities varied across studies, with a third of the included studies reporting that, compared with men, women were less likely to receive a combination of care, one-third of studies found no sex disparities, and one-third found that women were more likely to receive a combination of care than men (**Figure 10**).

DISCUSSION

This systematic review including 81 studies showed that the presence, magnitude, and direction of sex disparities in the assessment of cardiovascular risk factors and screening of diabetes-related complications varied considerably across studies, with some evidence suggesting that women, compared with men, may be more likely to receive retinopathy screening and less likely to receive foot exams. In addition, only two studies reported on the assessment of smoking status; both showing that women were more likely to be screened. Overall, screening rates can be improved for both sexes.

To our knowledge, this is the first systematic review studying sex disparities in the assessment and screening of cardiovascular

Author, year	Country	% Screened		М		OR/RR [95% CI]
Mier et al, 2012	US-Mexico	62	NR	NR	⊢ •−+1	0.49 [0.21, 1.11]
Kilbourne et al, 2011	US	83	NR	NR		0.52 [0.32, 0.83] *
Mtuya et al., 2016±	Tanzania	25	21	30		0.65 [0.32, 1.32]
Tannenbaum et al, 2016	US	56	NR	NR	⊢ • 	0.75 [0.38, 1.49]
Lawrenson et al., 2009	NZ	NR	62	68		0.76 [0.56, 1.04]
Lee et al, 2014	US	31	31	32	-	0.86 [0.45, 1.62]
Murchison et al, 2017	US	42	40	44	⊢ ∎-	0.86 [0.70, 1.06]
Moreton et al., 2017±	England	83	82	83	 - 	0.91 [0.85, 0.98] *
Rossi et al, 2013	Italy	33	31	34	÷	0.91 [0.90, 0.92] *
Mwangi et al, 2017	Kenya	13	13	14	⊢	0.91 [0.41, 1.67]
Baviera et al, 2014	Italy	33	32	34	H	0.94 [0.92, 0.96] *
Gnavi et al, 2009#	Italy	24^^^	23^^^	25^^^	-	0.95 [0.92, 0.99] *
MacLennan et al, 2014	US	33	33	33	 	0.95 [0.74, 1.21]
Williams et al, 2010	US	72^	NR	NR		0.96 [0.74, 1.27]
Whyte et al, 2019	England	26	NR	NR		0.96 [0.92, 1.00]
Hatef et al, 2015	US	56	NR	NR	⊢∎-1	1.00 [0.89, 1.13]
Chien et al, 2012	US	NR	NR	NR	i 🖡 i	1.01 [0.85, 1.17]
Kiran et al, 2012	Canada	64	NR	NR		1.04 [1.03, 1.05] *
Comer-HaGans et al, 2020	US	NR	NR	NR	H - -1	1.04 [0.93, 1.18]
Fraser et al., 2011	England	90	90	90	· ·	1.05 [0.98, 1.12]
Devkota et al, 2015	US	37	39	35		1.05 [0.58, 1.88]
An et al, 2018	US	71	72	71	, H	1.05 [1.03, 1.08] *
Kirkbride et al, 2009	US	46	NR	NR	10 H a -1	1.06 [0.95, 1.18]
Foreman et al, 2017	Australia	63	62	64		1.06 [0.78, 1.45]
Bartels et al, 2012#	US	NR	NR	NR	1	1.07 [1.06, 1.08] *
Chen et al, 2014	US	62^^	NR	NR	т Ш	1.08 [1.04, 1.12] *
Tomio et al, 2010	Japan	21	NR	NR		1.09 [0.73, 1.63]
Casanova et al, 2015	France	42	NR	NR		1.09 [1.08, 1.10] *
Stefos et al, 2011	US	81	NR	NR		1.12 [0.95, 1.33]
Kreft et al, 2018	Germany	62	61	63		1.12 [1.08, 1.15] *
Kovács et al, 2019	Hungary	40	NR	NR	1	1.12 [1.11, 1.13] *
Green et al, 2010	US	45	NR	NR	π L=J	1.13 [1.03, 1.24] *
Gulliford et al., 2010±	England	78	78	77		1.16 [1.05, 1.27] *
Youn et al. 2020	Korea	35	36	34		
Wei et al, 2020	Switzerland	44	47			1.16 [1.08, 1.25] *
				43		1.17 [1.13, 1.22] *
Bakke et al, 2019	Norway	60	NR	NR		1.18 [1.06, 1.32] *
Sieng et al, 2015	Thailand	50	NR	NR	1 1 - 1	1.20 [1.12, 1.29] *
Hwang et al, 2015	Canada	72^	74^	71^		1.22 [0.83, 1.78]
Kamat et al, 2016	US	NR	NR	NR		1.22 [0.97, 1.54]
Dallo et al, 2019	US	44	NR	NR		1.28 [1.16, 1.43] *
Billimek et al, 2015	US	59	59	58		1.30 [1.02, 1.66] *
Rim et al, 2013	Korea	38	40	35		1.40 [1.00, 1.90]
Kawamura et al, 2018	Japan	34	NR	NR		1.45 [1.30, 1.61] ★
Wang et al, 2010	China	33	36	29		1.50 [1.03, 2.18] ★
Baumeister et al, 2015	Germany	56	59	54		1.51 [0.96, 2.41]
Reichard et al, 2012	US	87	88	84		1.60 [1.30, 1.97] ★
Greenan et al., 2019±	Ireland	81	85	79	 	1.67 [1.15, 2.44] *
Tanaka et al, 2016	Japan	33	NR	NR		1.69 [1.56, 1.85] ★
						1
					0 0.5 1 1.5 2	2.5

FIGURE 7 | Retinopathy screening, expressed as adjusted odds ratios (OR) or relative risks (RR) with corresponding 95% confidence intervals (CI). Two studies are not presented in this figure because of their measure of association: Swietek et al. (33): Average Marginal Effect, (SE; p-value): 0.017 (-0.0043; <0.01 (women more likely to receive screening), Du et al. (92): Prevalence difference (95% CI): 12.6 (4.1;21.2). W = % of screened women; M = % of screened men; US, United States; UK, United Kingdom; # = Relative risk; ^ = 662 weighted %; ^^ = assumed to be weighted %; ^^^ = Kaplan-Meyer estimate; ± = Studies assessing screening adherence after screening invitation. Men = reference. * = statistically significant.

Author, year	Country	% Screened	W	м		OR/RR [95% CI]
Kilbourne et al., 2011	US	81	NR	NR		0.50 [0.30, 0.85]*
Devkota et al., 2015	US	38	33	43		0.52 [0.30, 0.90]*
Al-Sayah et al., 2015	Canada	41	38	45	- -	0.79 [0.70, 0.90]*
Comer-HaGans et al., 2020	US	NR	NR	NR		0.83 [0.75, 0.93] *
Chen et al., 2014	US	68^	NR	NR	H e H	0.85 [0.81, 0.89]*
Williams et al., 2010	US	71^	NR	NR		0.89 [0.66, 1.20]
Rossi et al., 2013	Italy	13	12	14	•	0.90 [0.88, 0.92] *
National Diabetes Audit 2017-2018	UK	86	NR	NR	+	0.99 [0.98, 1.00]
Bakke et al., 2019	Norway	28	NR	NR	⊷ − −1	1.00 [0.88, 1.14]
Sieng et al., 2015	Thailand	63	NR	NR		1.12 [1.04, 1.21]*
Kamat et al., 2019	US	NR	NR	NR	, ,	1.14 [0.86, 1.51]
Billimek et al., 2015	US	99	99	99		1.30 [0.44, 3.86]
					0.4 0.8 1 1.2 1.6	

FIGURE 8 | Foot exams, expressed as adjusted odds ratios (OR) with corresponding 95% confidence intervals (Cl). One study is not presented in this figure because of the measure of association: Du et al., (92): Prevalence difference (95% Cl 4.2 (-6.4; 14.9).W = % of screened women; M = % of screened men; US, United States; UK, United Kingdom; ^ = assumed to be weighted %. % Chen et al. extracted from the last available year. Men = reference. * = statistically significant.

risk factors and diabetes-related complications among individuals with diabetes. A recent meta-analysis, including 22 studies with 4,754,782 individuals from the general population in primary care setting, showed that assessment rates of CVD risk scores and risk factors were similar between the sexes (93). In contrast to our study, the authors did find evidence of women being less likely to be assessed for smoking (93). Nevertheless, the results were comparable to our study in that no consistent pattern in risk factor assessment and complication screening favoring either men or women was found and screening rates could be improved for both sexes.

Assessment of cardiovascular risk factors and screening for diabetes-related complications is critical in guiding treatment decisions. The present study demonstrates that there is no consistent pattern in screening activities favoring men or women, suggesting that disparities in risk factor assessment and screening activities do not account for the higher relative risk of CVD conferred by diabetes previously found in women compared with men (2–8). However, other factors related to the uptake and provision of healthcare, such as treatment and adherence, may still be involved in explaining these sex differences. Although assessment of cardiovascular risk factors is one of the first steps in guiding treatment decisions, it may not necessarily be followed by equal treatment. For example, a recently published meta-analyses, including data from 2.2 million individuals in primary care, showed that women at high risk or with established CVD were less likely to be prescribed aspirin, statins, and angiotensin-converting enzyme (ACE) inhibitors, and more likely to be prescribed diuretics, than men (94). Other studies have suggested that women are less adherent to statins than men (95–97). Differences in biology may also impact women's excess risk of CVD and it has previously been hypothesized that women experience a relatively greater increase of cardiovascular risk factor levels in the transition from normal glycaemia to diabetes (98). Differences in body anthromorphy and fat storage may be of particular interest in explaining the women's excess risk of CVD, as fat distribution differs by sex. Sex differences in fat distribution may impact the duration of the transition from normoglycemia to overt diabetes and consequently impact the increase of other related cardiovascular risk factor levels (2).

Strengths and Limitations

The main strength of this systematic review is the inclusion large number of studies providing sex-specific data. The majority of studies included more than 1000 individuals, of which 41 (51%) studies included over 10.000 individuals. This study also has several limitations. First, there was substantial heterogeneity between studies regarding patient population, outcome definitions, and data source and no meta-analyses were performed. Second, there was a lack of studies that specifically evaluated risk factor assessment in individuals diagnosed with type

Author, year	Country	% Screened	w	м	OR/RR [95% CI]
National Diabetes Audit 2017-2018	UK	95	NR	NR	 1.57 [1.55, 1.59]*
Guthrie et al., 2009	Scotland	96	96.8	95.8	1.27 [1.02. 1.58]*
				0.8 Men do better	1 1.2 1.6 Women do better

Author, year	Country	% Screened	W	М		OR/RR [95% CI]
Willis et al., 2017 ¹	England	59	NR	NR	H	0.81 [0.77, 0.83]*
Chen et al., 2010 ²	US	58	NR	NR	HER	0.86 [0.82, 0.89] *
Guthrie et al., 2009 ³	Scotland	88	NR	NR		0.87 [0.76, 0.98]*
Mounce et al., 2015 ⁴	England	68	NR	NR	·	0.91 [0.61, 1.35]
National Diabetes Audit ⁵ 2017-2018	UK	58	56	58	•	0.91 [0.90, 0.91]*
Kiran et al., 2012 ⁶	Canada	27	NR	NR	-	0.96 [0.95, 0.98] *
Gnavi et al., 2009# ⁷	Italy	36^	35^	37^	-	0.98 [0.95, 1.01]
De Jong et al., 2019# ⁸	The Netherlands	s 84	83	86	-	1.01 [1.00, 1.03] *
Gregg et al., 2010 ⁹	US	70	NR	NR	·	1.02 [0.92, 1.29]
Wilf-Miron et al., 2010 ¹⁰	Israel	24	25	24	-=-	1.05 [1.00, 1.09] 🕯
Lu et al., 2020 ¹¹	US	28	NR	NR	•	1.05 [1.03, 1.07] *
Bakke et al., 2019 ¹²	Norway	35	NR	NR	. ⊢ ∎—(1.06 [0.95, 1.20]
Ng et al., 2010 ¹³	US	43^	NR	NR	r ∔∎ (1.09 [0.92, 1.29]
Sieng et al., 2015 ¹⁴	Thailand	28	NR	NR	⊢ ∎	1.11 [1.03, 1.21] *
Druss et al., 2012 ¹⁵	US	38	NR	NR	18-1	1.16 [1.13, 1.20] *
					r l	1
					0.5 1 1	.5

FIGURE 10 | Combination of risk factor assessment and screening, expressed as adjusted odds ratios (OR) or risk ratios (RR) with corresponding 95% confidence intervals (CI). # = risk ratio; ^ = Kaplan-Meyer estimates; * = statistically significant. W = % of screened women; M = % of screened men; Men = reference. 1 = All measurements received within 12 months: blood pressure, HbA1c, cholesterol, urine albumin: creatinine ratio/protein:creatinine or proteinuria, eGFR or serum creatinine, foot and eye exams, BMI, smoking status, within 15 months (6 for HbA1c). 2 = Receiving at least 2 HbA1c measurements and 1 LDL measurement received within 12 months: 3 = All measurements received within 12 months: HbA1c, proteinuria, foot exam. 5 = All measurements received within 15 months: HbA1c, blood pressure, cholesterol, smoking status. 4 = At least one of the following measurements received within 12 months: HbA1c, proteinuria, foot exam. 5 = All measurements received within 24 months: eye exam, four HbA1c tests, and two cholesterol tests. 7 = Assessment of HbA1c and at least two measurements received within 12 months: HbA1c, blood pressure, total cholesterol, LDL, HDL, or BMI. 9 = All measurements received within 36 months: HbA1c, lipid profile, urine albumin, eye exam, and foot exam. 10 = All measurements received within 12 months: HbA1c, blood pressure and foot exams, bload pressure and BMI. 11 = All measurements received within 12 months: HbA1c, blood pressure, total cholesterol, LDL, HDL, or BMI. 9 = All measurements received within 36 months: HbA1c, lipid profile, urine albumin, eye exam, and foot exam. 10 = All measurements received within 12 months: HbA1c, lipid profile, urine albumin, eye exam, and foot exams. 10 = All measurements received within 30 months. HbA1c, lipid profile, urine albumin, eye exam, and foot exams. 10 = All measurements received within 12 months: HbA1c, LDL, eye exam, and medical attention for nephropathy (including screening and treatment). 12 = Receiving at least two out of three measurem

1 diabetes. Of the studies that included individuals with diabetes without specifying the subtype, we assume that majority of the included study participants were diagnosed with type 2 diabetes. The results of this systematic review are therefore mainly applicable to those with type 2 diabetes. An appropriate method to study sex disparities separately for type 1 and type 2 diabetes would be an individual participants data (IPD) analysis, and future research should attempt to obtain individual-level patient data. Third, the majority of studies were from Europe and Northern America, thereby limiting the generalizability to other parts of the world. Fourth, screening rates varied widely between studies and across the outcomes of interest and can be improved for both sexes, nonetheless strategies on how to improve these rates are not discussed in this review. Further research is needed to explore the reasons for the suboptimal screening rates found in both sexes within the context of local and national healthcare settings.

CONCLUSION

Mixed findings were found regarding the presence, magnitude, and direction of sex disparities with regard to the assessment of cardiovascular risk factors and screening for diabetes-related complications. Overall, no consistent pattern favoring men or women was found and screening rates can be improved for both sexes.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

RV, SP, MB, and MJ conceived the research. MJ and RV conducted the analyses and drafted the manuscript. All authors contributed critical intellectual content and made important revisions to the manuscript. RV is the guarantor of this work. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by the Netherlands Organization forHealth Research and Development (ZonMw), Gender andHealth Programme (Project no 849200001).

REFERENCES

- 1. IDF. *Atlas 9th edition* International Diabetes Federation 2019. Available at: https://diabetesatlas.org/en/resources/.
- de Ritter R, de Jong M, Vos RC, van der Kallen CJH, Sep SJS, Woodward M, et al. Sex differences in the risk of vascular disease associated with diabetes. *Biol Sex Differ* (2020) 11:1. doi: 10.1186/s13293-019-0277-z
- Millett ERC, Peters SAE, Woodward M. Sex differences in risk factors for myocardial infarction: cohort study of UK Biobank participants. *BMJ* (2018) 363:k4247. doi: 10.1136/bmj.k4247
- de Jong M, Woodward M, Peters SAE. Diabetes, Glycated Hemoglobin, and the Risk of Myocardial Infarction in Women and Men: A Prospective Cohort Study of the UK Biobank. *Diabetes Care* (2020) 43(9):2050–9. doi: 10.2337/ dc19-2363
- Peters SAE, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. *Diabetologia* (2014) 57:1542–51. doi: 10.1007/s00125-014-3260-6
- Peters SAE, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. *Lancet (London England)* (2014) 383:1973–80. doi: 10.1016/S0140-6736(14)60040-4
- Ohkuma T, Komorita Y, Peters SAE, Woodward M. Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals. *Diabetologia* (2019) 62:1550–60. doi: 10.1007/s00125-019-4926-x
- Lee W, Cheung A, Cape D, Zinman B. Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. *Diabetes Care* (2000) 23:962–8. doi: 10.2337/diacare.23.7.962
- Chatterjee S, Peters SAE, Woodward M, Arango SM, Batty GD, Beckett N, et al. Type 2 Diabetes as a Risk Factor for Dementia in Women Compared With Men: A Pooled Analysis of 2.3 Million People Comprising More Than 100,000 Cases of Dementia. *Diabetes Care* (2016) 39:300–7. doi: 10.2337/ dc15-1588
- Shen Y, Cai R, Sun J, Dong X, Huang R, Tian S, et al. Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men: a systematic review and meta-analysis. *Endocrine* (2017) 55:66–76. doi: 10.1007/s12020-016-1014-6
- Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PloS Med* (2009) 6:e1000097. doi: 10.1371/journal.pmed.1000097
- Badampudi D, Wohlin C, Petersen K. Experiences from using snowballing and database searches in systematic literature studies. In: . Proceedings of the 19th International Conference on Evaluation and Assessment in Software Engineering - EASE "15. ACM Press (2015). p. 1–10. doi: 10.1145/ 2745802.2745818
- 13. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Logos M, Tugwell P, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. The Ottawa Hospital Research Institute1–2.http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
- Tan SH, Tan SB. The correct interpretation of confidence intervals. Proc Singapore Healthc (2010) 19:276–8. doi: 10.1177/201010581001900316
- National Diabetes Audit. NHS Digital NHS digital. Available at: https://digital. nhs.uk/data-and-information/publications/statistical/national-diabetes-audit.
- Murchison AP, Hark L, Pizzi LT, Dai Y, Mayro EL, Storey PP, et al. Nonadherence to eye care in people with diabetes. *BMJ Open Diabetes Res Care* (2017) 5:1–10. doi: 10.1136/bmjdrc-2016-000333
- 17. Tanaka H, Tomio J, Sugiyama T, Kobayashi Y. Process quality of diabetes care under favorable access to healthcare: A 2-year longitudinal study using claims

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/ fendo.2021.617902/full#supplementary-material

data in Japan. BMJ Open Diabetes Res Care (2016) 4:e000291. doi: 10.1136/ bmjdrc-2016-000291

- Sieng S, Thinkamrop B, Hurst C. Achievement of Processes of Care for Patients with Type 2 Diabetes in General Medical Clinics and Specialist Diabetes Clinics in Thailand. *Epidemiol Open Access* (2015) 1–9. doi: 10.4172/ 2161-1165.S2-004
- Baumeister SE, Baumeister SE, Schomerus G, Andersen RM, Tost F, Markus MRP, et al. Trends of barriers to eye care among adults with diagnosed diabetes in Germany, 1997-2012. *Nutr Metab Cardiovasc Dis* (2015) 25:906– 15. doi: 10.1016/j.numecd.2015.07.003
- Hatef E, Vanderver BG, Fagan P, Albert M, Alexander M. Annual diabetic eye examinations in a managed care Medicaid population. *Am J Manage Care* (2015) 21:e297–302.
- Kamat S, Gousse Y, Muzumdar J, Gu A. Trends and Disparities in Quality of Diabetes Care in the US: The National Health and Nutrition Examination Survey, 1999-2016. *Inov Pharm* (2019) 10:17. doi: 10.24926/iip.v10i4.2064
- Bennett KJ, McDermott S, Mann JR, Hardin J. Receipt of recommended services among patients with selected disabling conditions and diabetes. *Disabil Health J* (2017) 10:58–64. doi: 10.1016/j.dhjo.2016.09.001
- An JJ, Niu F, Turpcu A, Rajput Y, Cheetham TC. Adherence to the American Diabetes Association retinal screening guidelines for population with diabetes in the United States. *Ophthalmic Epidemiol* (2018) 25:257–65. doi: 10.1080/ 09286586.2018.1424344
- Mwangi N, Macleod D, Gichuhi S, Muthami L, Moorman C, Bascaran C, et al. Predictors of uptake of eye examination in people living with diabetes mellitus in three counties of Kenya. *Trop Med Health* (2017) 45:1–10. doi: 10.1186/ s41182-017-0080-7
- 25. LeBlanc E, Bélanger M, Thibault V, Babin L, Greene B, Halpine S, et al. Influence of a Pay-for-Performance Program on Glycemic Control in Patients Living with Diabetes by Family Physicians in a Canadian Province. *Can J Diabetes* (2017) 41:190–6. doi: 10.1016/j.jcjd.2016.09.008
- Foreman J, KeelS, XieJ, Van WijngaardenP, TaylorHR, DiraniM, et al. Adherence to diabetic eye examination guidelines in Australia: The national eye health survey. *Med J Aust* (2017) 206:402–6. doi: 10.5694/mja16.00989
- WhyteMB, HintonW, McGovernA, Van VlymenJ, FerreiraF, WhyteMB, et al. Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysis. *PloS Med* (2019) 16:1–18. doi: 10.1371/journal.pmed.1002942
- de Jong M, Vos RC, de Ritter R, van der Kallen CJ, Sep SJ, Woodward M, et al. Sex differences in cardiovascular risk management for people with diabetes in primary care: A cross-sectional study. *BJGP Open* (2019) 3:1–11. doi: 10.3399/ bjgpopen19X101645
- BakkeÅ, TranAT, DalenI, CooperJG, LøvaasKF, JenumAk, et al. Population, general practitioner and practice characteristics are associated with screening procedures for microvascular complications in Type 2 diabetes care in Norway. *Diabet Med* (2019) 36:1431–43. doi: 10.1111/dme.13842
- 30. Rim THT, Byun IH, Kim HS, Lee SY, Yoon JS. Factors associated with diabetic retinopathy and nephropathy screening in Korea: The third and fourth Korea national health and nutrition examination survey (KNHANES III and IV). J Korean Med Sci (2013) 28:814–20. doi: 10.3346/jkms.2013.28.6.814
- Wei W, Gruebner O, Von Wyl V, Dressel H, Ulyte A, Brüngger B, et al. Exploring geographic variation of and influencing factors for utilization of four diabetes management measures in Swiss population using claims data. *BMJ Open Diabetes Res Care* (2020) 8:1–11. doi: 10.1136/bmjdrc-2019-001059
- 32. Lu Z, Cogan L, McDermott S, Lauer E, Lindner S, Tracy K, et al. Disparities in diabetes management among medicaid recipients with intellectual and developmental disabilities (IDD): Evidence from five U.S. states. *Disabil Health J* (2020) 13:100880. doi: 10.1016/j.dhjo.2019.100880

- Swietek KE, Gaynes BN, Jackson GL, Weinberger M, Domino ME. Effect of the Patient-Centered Medical Home on Racial Disparities in Quality of Care. *J Gen Intern Med* (2020) 35:2304–13. doi: 10.1007/s11606-020-05729-x
- Meier R, Valeri F, Senn O, Rosemann T, Chmiel C. Quality performance and associated factors in Swiss diabetes care – A cross-sectional study. *PloS One* (2020) 15:1–14. doi: 10.1371/journal.pone.0232686
- Hirst JA, Farmer AJ, Smith MC, Stevens RJ. Timings for HbA 1c testing in people with diabetes are associated with incentive payments: an analysis of UK primary care data. *Diabet Med* (2019) 36:36–43. doi: 10.1111/dme.13810
- Mtuya C, Cleland CR, Philippin H, Paulo K, Njau B, Makupa WU, et al. Reasons for poor follow-up of diabetic retinopathy patients after screening in Tanzania: A cross-sectional study. *BMC Ophthalmol* (2016) 16:1–7. doi: 10.1186/s12886-016-0288-z
- 37. Fraser DS, Watkinson GE, Rennie CA, King D, Sanderson H, Edwards L, et al. Sociodemographic differences in diabetic retinopathy screening; using patient-level primary care data for health equity audit. *Clin Audit* (2011) 7. doi: 10.2147/ca.s25313
- Greenan E, Salim M, Coakley DN, James M. The effect of geodemographic factors on the attendance rates at a regional diabetic retinopathy treatment centre. *Ir J Med Sci* (2019) 188:1207–12. doi: 10.1007/s11845-019-02009-4
- Moreton RBR, Stratton IM, Chave SJ, Lipinski H, Scanlon PH. Factors determining uptake of diabetic retinopathy screening in Oxfordshire. *Diabet Med* (2017) 34:993–9. doi: 10.1111/dme.13350
- WangD, Ding X, He M, Yan L, Kuang J, Geng Q, et al. Use of eye care services among diabetic patients in Urban and Rural China. *Ophthalmology* (2010) 117:1755–62. doi: 10.1016/j.ophtha.2010.01.019
- Gnavi R, Picariello R, La Karaghiosoff L, Costa G, Giorda C. Determinants of quality in diabetes care process: The population-based Torino study. *Diabetes Care* (2009) 32:1986–92. doi: 10.2337/dc09-0647
- Kirkbride K, Wallace N. Rural health clinics and diabetes-related primary care for medicaid beneficiaries in oregon. J Rural Heal (2009) 25:247–52. doi: 10.1111/j.1748-0361.2009.00226.x
- Guthrie B, Emslie-Smith A, Morris AD. Which people with Type 2 diabetes achieve good control of intermediate outcomes? Population database study in a UK region. *Diabet Med* (2009) 26:1269–76. doi: 10.1111/j.1464-5491.2009.02837.x
- Tomio J, Toyokawa S, Tanihara S, Inoue K, Kobayashi Y. Quality of care for diabetes patients using National Health Insurance claims data in Japan. J Eval Clin Pract (2010) 16:1164–9. doi: 10.1111/j.1365-2753.2009.01287.x
- 45. Williams SL, Haskard-Zolnierek KB, Banta JE, Haviland MG, Dimatteo MR, Anderson D, et al. Serious psychological distress and diabetes care among California adults. *Int J Psychiatry Med* (2010) 40:233–45. doi: 10.2190/ PM.40.3.a
- Green JL, Gazmararian JA, Rask KJ, Druss BG. Quality of diabetes care for underserved patients with and without mental illness: Site of care matters. *Psychiatr Serv* (2010) 61:1204–10. doi: 10.1176/ps.2010.61.12.1204
- Chen JY, Tian H, Juarez DT, Hodges KA Jr, Brand JC, Chung RS, et al. The effect of a PPO pay-for-performance program on patients with diabetes. *Am J Manage Care* (2010) 16:11–9.
- Ng J, Scholle SH. Disparities in Quality of Care for Midlife Adults (Ages 45-64) Versus Older Adults (Ages >65). (2010), 1–72.
- 49. Gregg EW, Karter AJ, Gerzoff RB, Safford M, Brown AF, Tseng CW, et al. Characteristics of Insured Patients with Persistent Gaps in Diabetes Care Services: The Translating Research into Action for Diabetes (TRIAD) Study. *Med Care* (2010) 48:31–7. doi: 10.1097/MLR.0b013e3181bd4783
- Stefos T, Burgess JF Jr, Mayo-Smith MF, Frisbee KL, Harvey HB, Lehner L, et al. The effect of physician panel size on health care outcomes. *Heal Serv Manage Res* (2011) 24:96–105. doi: 10.1258/hsmr.2011.011001
- 51. Kilbourne AM, Pirraglia PA, Lai Z, Bauer MS, Charns MP, Greenwald D, et al. Quality of general medical care among patients with serious mental illness: Does colocation of services matter? *Psychiatr Serv* (2011) 62:922–8. doi: 10.1176/ps.62.8.pss6208_0922
- Bartels CM, Saucier JM, Thorpe CT, Kind AJ, Pandhi N, Hansen KE, et al. Monitoring diabetes in patients with and without rheumatoid arthritis: a Medicare study. *Arthritis Res Ther* (2012) 14:1–9. doi: 10.1186/ar3915
- 53. Mier N, Wang X, Lee Smith M, Irizarry D, Harvey HB, Treviño L, et al. Factors influencing health care utilization in older Hispanics with diabetes

along the Texas-Mexico border. *Popul Health Manage* (2012) 15:149–56. doi: 10.1089/pop.2011.0044

- Gold R, DeVoe JE, McIntire PJ, Puro JE, Chauvie SL, Shah AR, et al. Receipt of diabetes preventive care among safety net patients associated with differing levels of insurance coverage. J Am Board Fam Med (2012) 25:42–9. doi: 10.3122/jabfm.2012.01.110142
- Kiran T, Victor JC, Kopp A, Shah BR, Glazier RH. The relationship between financial incentives and quality of diabetes care in Ontario, Canada. *Diabetes Care* (2012) 35:1038–46. doi: 10.2337/dc11-1402
- Chien AT, Eastman D, Li Z, Rosenthal MB. Impact of a pay for performance program to improve diabetes care in the safety net. *Prev Med (Baltim)* (2012) 55:S80–5. doi: 10.1016/j.ypmed.2012.05.004
- Yu MK, Lyles CR, Bent-Shaw LA, Young BA. Sex disparities in diabetes process of care measures and self-care in high-risk patients. J Diabetes Res (2013) 2013:575814. doi: 10.1155/2013/575814
- Hellemons ME, Denig P, De Zeeuw D, Voorham J, Lambers Heerspink HJ. Is albuminuria screening and treatment optimal in patients with type 2 diabetes in primary care? Observational data of the GIANTT cohort. *Nephrol Dial Transplant* (2013) 28:706–15. doi: 10.1093/ndt/gfs567
- Maclennan PA, McGwin G Jr, Heckemeyer C, Lolley VR, Hullett S, Saaddine J, et al. Eye Care Utilization among a High-Risk Diabetic Population Seen in a Public Hospital's Clinics. *JAMA Ophthalmol* (2014) 132:162–7. doi: 10.1001/ jamaophthalmol.2013.6046
- 60. Lee DJ, Kumar N, Feuer WJ, Chou CF, Rosa PR, Schiffman J, et al. Dilated eye examination screening guideline compliance among patients with diabetes without a diabetic retinopathy diagnosis: the role of geographic access. *BMJ Open Diabetes Res Care* (2014) 2:e000031. doi: 10.1136/bmjdrc-2014-000031
- Chen R, Cheadle A, Johnson D, Duran B. US Trends in Receipt of Appropriate Diabetes Clinical and Self-care From 2001 to 2010 and Racial/Ethnic Disparities in Care. *Diabetes Educ* (2014) 40:756–66. doi: 10.1177/ 0145721714546721
- Buja A, Gini R, Visca M, Damiani G, Federico B, Donato D, et al. Need and disparities in primary care management of patients with diabetes. *BMC Endocr Disord* (2014) 14:1–8. doi: 10.1186/1472-6823-14-56
- 63. Casanova L, Roses F, Carrier H, Gentile G, Verger P. Evolution of paraclinical monitoring between 2008 and 2011of treated type 2 diabetic patients. *exercer la revue francophone de médecine générale* (2015) 26:205–12.
- Liang H, Kennedy C, Manne S, Lin JH-L, Dolin P. Monitoring for proteinuria in patients with type 2 diabetes mellitus. *BMJ Open Diabetes Res Care* (2015) 3:e000071. doi: 10.1136/bmjdrc-2014-000071
- Hwang J, Rudnisky C, Bowen S, Johnson JA. Socioeconomic factors associated with visual impairment and ophthalmic care utilization in patients with type II diabetes. *Can J Ophthalmol* (2015) 50:119–26. doi: 10.1016/j.jcjo.2014.11.014
- 66. Tannenbaum SL, McClure LA, Zheng DD, Lam BL, Arheart KL, Joslin CE, et al. Ocular screening adherence across hispanic/latino heritage groups with diabetes: Results from the ocular SOL ancillary to the miami site of the hispanic community health study/study of latinos (HCHS/SOL). BMJ Open Diabetes Res Care (2016) 4. doi: 10.1136/bmjdrc-2016-000236
- Rossaneis MA, Haddad M, do CFL, de F Mathias TA, Marcon SS. Diferenças entre mulheres e homens diabéticos no autocuidado com os pés e estilo de vida. *Rev Lat Am Enfermagem* (2016) 24:e2761. doi: 10.1590/1518-8345.1203.2761
- Van Doorn-Klomberg AL, Braspenning JCC, Atsma F, Jansen B, Bouma M, Wolters R, et al. Patient Characteristics Associated with Measurement of Routine Diabetes Care: An Observational Study. *PloS One* (2015) 10. doi: 10.1371/journal.pone.0121845
- Druss BG, Liping Z, Cummings JR, Shim RS, Rust GS, Marcus SC, et al. Mental comorbidity and quality of diabetes care under Medicaid: a 50-state analysis. *Med Care* (2012) 50:428–33. doi: 10.1097/MLR.0b013e318245a528
- Kawamura T, Sato I, Tamura H, Nakao YM, Kawakami K. Influence of comorbidities on the implementation of the fundus examination in patients with newly diagnosed type 2 diabetes. *Jpn J Ophthalmol* (2018) 62:68–76. doi: 10.1007/s10384-017-0551-8
- 71. Ibáñez B, Galbete A, Goñi MJ, Forga L, Arnedo L, Aizpuru F, et al. Socioeconomic inequalities in cardiometabolic control in patients with type 2 diabetes. *BMC Public Health* (2018) 18:408. doi: 10.1186/s12889-018-5269-0

- 72. Kovács N, Pálinkás A, Sipos V, Nagy A, Nouh H, Kőrösi L, et al. Factors Associated with Practice-Level Performance Indicators in Primary Health Care in Hungary: A Nationwide Cross-Sectional Study. Int J Environ Res Public Health (2019) 16:3153. doi: 10.3390/ijerph16173153
- 73. Yoo K-H, Shin DW, Cho MH, Kim SH, Bahk HJ, Kim SH, et al. Regional variations in frequency of glycosylated hemoglobin (HbA1c) monitoring in Korea: A multilevel analysis of nationwide data. *Diabetes Res Clin Pract* (2017) 131:61–9. doi: 10.1016/j.diabres.2017.06.008
- Reichard A, Stolzle H, Sella AC, Shireman TI. Quality of diabetes care for adults with physical disabilities in Kansas. *Disabil Health J* (2012) 5:34–40. doi: 10.1016/j.dhjo.2011.09.003
- Devkota BP, Ansstas M, Scherrer JF, Salas J, Budhathoki C. Internal Medicine Resident Training and Provision of Diabetes Quality of Care Indicators. *Can J Diabetes* (2015) 39:133–7. doi: 10.1016/j.jcjd.2014.10.001
- Williams JS, Bishu KG, St Germain A, Egede LE. Trends in sex differences in the receipt of quality of care indicators among adults with diabetes: United States 2002-2011. BMC Endocr Disord (2017) 17:31. doi: 10.1016/j.jcjd.2014.10.001
- Dallo FJ, Ruterbusch JJ, McCullough JR, Sreedhar S, Schwartz K, Mulhem E, et al. Diabetes Management Among Arab Americans Who Sought Care at a Large Metropolitan Hospital System in Michigan. J Immigr Minor Heal (2019) 21:490–6. doi: 10.1007/s10903-018-0777-7
- Lawrenson R, Gibbons V, Joshy G, Choi P. Are there disparities in care in people with diabetes? A review of care provided in general practice. J Prim Health Care (2009) 1:177–83. doi: 10.1071/HC09177
- Wilf-Miron R, Peled R, Yaari E, Shem-Tov O, Weinner V, Porath A, et al. Disparities in diabetes care: role of the patient's socio-demographic characteristics. *BMC Public Health* (2010) 10:729. doi: 10.1186/1471-2458-10-729
- Naicker K, Liddy C, Singh J, Taljaard M, Hogg W. Quality of cardiovascular disease care in Ontario's primary care practices: a cross sectional study examining differences in guideline adherence by patient sex. *BMC Fam Pract* (2014) 15:123. doi: 10.1186/1471-2296-15-123
- Baviera M, Santalucia P, Cortessi L, Marzona I, Tattamanti M, Avanzini F, et al. Sex differences in cardiovascular outcomes, pharmacological treatments and indicators of care in patients with newly diagnosed diabetes: Analyses on administrative database. *Eur J Intern Med* (2014) 25:270–5. doi: 10.1016/ j.ejim.2014.01.022
- Willis TA, West R, Cortessi L, Marzona I, Tattamanti M, Avanzini F, et al. Variations in achievement of evidence-based, high-impact quality indicators in general practice: An observational study. *PloS One* (2017) 12:e0177949. doi: 10.1371/journal.pone.0177949
- Bird CE, Manocchia M, Tomblin B, Payne P, Kulakodlu M, Iacolo E, et al. Mapping the Gaps: Gender Differences in Preventive Cardiovascular Care among Managed Care Members in Four Metropolitan Areas. Womens Health Issues (2018) 28:446–55. doi: 10.1016/j.whi.2018.04.008
- 84. Billimek J, Malik S, Sorkin DH, Schmalbach P, Ngo-Metzger Q, Greenfield S, et al. Understanding disparities in lipid management among patients with type 2 diabetes: gender differences in medication nonadherence after treatment intensification. Womens Health Issues (2015) 25:6–12. doi: 10.1016/j.whi.2014.09.004
- 85. Rossi MC, Cristofaro MR, Gentile S, Lucisano G, Manicardi V, Mulas MF, et al. Sex disparities in the quality of diabetes care: Biological and cultural factors may play a different role for different outcomes: A cross-sectional observational study from the amd annals initiative. *Diabetes Care* (2013) 36:3162–8. doi: 10.2337/dc13-0184
- Mounce LTA, Steel N, Hardcastle AC, Henley WE, Bachmann MO, Campbell JL, et al. Patient characteristics predicting failure to receive indicated care for type 2 diabetes. *Diabetes Res Clin Pract* (2015) 107:247–58. doi: 10.1016/ j.diabres.2014.11.009

- Youn HM, Lee DW, Park EC. Association between community outpatient clinic care accessibility and the uptake of diabetic retinopathy screening: A multi-level analysis. *Prim Care Diabetes* (2020) 14(6):2–7. doi: 10.1016/ j.pcd.2020.02.010
- Al Sayah F, Soprovich A, Qiu W, Edwards AL, Johnson JA. Diabetic Foot Disease, Self-Care and Clinical Monitoring in Adults with Type 2 Diabetes: The Alberta's Caring for Diabetes (ABCD) Cohort Study. *Can J Diabetes* (2015) 39:S120–6. doi: 10.1016/j.jcjd.2015.05.006
- Gulliford M, Dodhia H, Chamley M, McCormick K, Mohamed M, Naithani S, et al. Socioeconomic and Ethnic Inequalities in Diabetes Retinal Screening. *Diabet Med* (2010) 27:282–8. doi: 10.1111/j.1464-5491.2010.02946.x
- Kreft D, McGuinness MB, Doblhammer G, Finger RP. Diabetic retinopathy screening in incident diabetes mellitus type 2 in Germany between 2004 and 2013 - A prospective cohort study based on health claims data. *PloS One* (2018) 13:e0195426. doi: 10.1371/journal.pone.0195426
- Comer-HaGans DL, Austin S, Ramamonjiarivelo Z, Matthews AK. Diabetes Standard of Care Among Individuals Who Have Diabetes With and Without Cognitive Limitation Disabilities. *Diabetes Educ* (2020) 46:94–107. doi: 10.1177/0145721719896262
- 92. Du Y, Baumert J, Paprott R, Neuhauser H, Heidemann C, Scheidt-Nave C, et al. Gender differences in cardiovascular risk profiles and diabetes care among adults with type 2 diabetes in Germany. (2019). doi: 10.1016/ j.diabet.2018.05.011
- Hyun KK, Millett ERC, Redfern J, Brieger D, Peters SAE, Woodward M, et al. Sex Differences in the Assessment of Cardiovascular Risk in Primary Health Care: A Systematic Review. *Heart Lung Circ* (2019) 28:1535–48. doi: 10.1016/ j.hlc.2019.04.005
- 94. Zhao M, Woodward M, Vaartjes I, Millett ERC, Klipstein-Grobusch K, Hyun K, et al. Sex Differences in Cardiovascular Medication Prescription in Primary Care: A Systematic Review and Meta-Analysis. J Am Heart Assoc (2020) 9: e014742. doi: 10.1161/JAHA.119.014742
- Lewey J, Shrank WH, Bowry ADK, Kilabuk E, Brennan TA, Choudhry NK, et al. Gender and racial disparities in adherence to statin therapy: A meta-analysis. *Am Heart J* (2013) 165:665–78.e1. doi: 10.1016/j.ahj. 2013.02.011
- Colantonio LD, Rosenson rs, Deng L, Monda KL, Dai Y, Farkouh ME, et al. Adherence to Statin Therapy Among US Adults Between 2007 and 2014. J Am Heart Assoc (2019) 8. doi: 10.1161/JAHA.118.010376
- Goldstein KM, Zullig LL, Bastian LA, Bosworth HB. Statin Adherence: Does Gender Matter? *Curr Atheroscler Rep* (2016) 18:63. doi: 10.1007/s11883-016-0619-9
- 98. de Ritter R, Simone SJS, van der Kallen CJH, Schram MT, Koster A, Kroon AA, et al. Adverse differences in cardiometabolic risk factor levels between individuals with prediabetes and normal glucose metabolism are more pronounced in women than in men: The Maastricht Study. BMJ Open Diabetes Res Care (2019). doi: 10.1136/bmjdrc-2019-000787

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 de Jong, Peters, de Ritter, van der Kallen, Sep, Woodward, Stehouwer, Bots and Vos. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.